

## Bone Therapeutics to present data from its Phase II/III trial with JTA-004 at the 2<sup>nd</sup> World Congress on Rheumatology & Orthopedics

**Gosselies, Belgium, 27 September 2019, 7am CEST – BONE THERAPEUTICS** (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases, announces that Dr. Olivier Godeaux, Chief Medical Officer of Bone Therapeutics, will give a keynote presentation at the 2<sup>nd</sup> [World Congress on Rheumatology & Orthopedics \(WCRO\)](#) in Paris, France, today at 10:45am CEST.

WCRO serves as an international platform to bring prominent speakers, renowned scientists, professors, deans, surgeons, physicians, medical and industrial professionals, and business delegates together to exchange new insights and to share recent progress in the field of rheumatology and orthopaedics. The event is supported by 20 orthopaedic societies in Europe, America and Asia and is expected to receive participants and experts from over 40 countries across the globe.

The oral presentation will discuss the results from the Phase II/III study with JTA-004, Bone Therapeutics' novel enriched protein solution, currently in development for the treatment of osteoarthritis of the knee.

### Presentation Details:

**Title:** *Safety and efficacy of intra-articular injection of JTA-004, a novel supplemented protein solution, in symptomatic knee osteoarthritis: a randomized, double-blind controlled phase II/III study*

**Authors:** Marie Bettonville<sup>1</sup>, Anne-Sophie Delmarcelle<sup>1</sup>, Marc Léon<sup>2</sup>, Bogdan Ster<sup>3</sup>, Jean-François Kaux<sup>4</sup>, Thierry Appelboom<sup>5</sup>, Joëlle Margaux<sup>6</sup>, Didier Urbin-Choffray<sup>7</sup>, Emilie Theunissen<sup>8</sup>, Tatiana Besse-Hammer<sup>9</sup>, Philippe De Greift<sup>10</sup>, Jiangang Qu<sup>11</sup>, Yves Fortems<sup>12</sup>, Séverine Verlinden<sup>13</sup>, and Olivier Godeaux<sup>1</sup>

**Date:** Friday, 27 September 2019

**Time:** 10:45 – 11:15am CEST

**Location:** Main Hall, Holiday Inn Paris - Porte de Clichy, France

<sup>1</sup>Bone Therapeutics S.A., Belgium; <sup>2</sup>CHU Ambroise Paré, Belgium; <sup>3</sup>CHU Saint-Pierre, Belgium; <sup>4</sup>University and University Hospital of Liège, Belgium; <sup>5</sup>Hôpitaux Iris Sud Molière Longchamp, Belgium; <sup>6</sup>CUB Erasme, Belgium; <sup>7</sup>CHR Citadelle, Belgium; <sup>8</sup>Clinique Saint-Pierre Ottignies, Belgium; <sup>9</sup>CHU Brugmann, Belgium; <sup>10</sup>CHR de Namur, Belgium; <sup>11</sup>Hôpitaux Iris Sud Etterbeek-Ixelles, Belgium; <sup>12</sup>AZ Sint Jozef, Belgium; <sup>13</sup>CHR Haute Senne, Belgium.

## ● About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy and an innovative biological product in later-stage clinical development across a number of disease areas, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics' core technology is based on its allogeneic cell therapy platform (ALLOB) which uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, cutting-edge manufacturing process.

The Company's ALLOB product pipeline includes a cell therapy product candidate that is expected to enter Phase II/III clinical development for the treatment of delayed-union fractures and a Phase II asset in patients undergoing a spinal fusion procedure. In addition, the Company is also developing an off-the-shelf protein solution, JTA-004, which is expected to enter Phase III development for the treatment of pain in knee osteoarthritis.

Bone Therapeutics' cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. Further information is available at [www.bonetherapeutics.com](http://www.bonetherapeutics.com).

## ● For further information, please contact:

### Bone Therapeutics SA

Thomas Lienard, Chief Executive Officer  
Jean-Luc Vandebroek, Chief Financial Officer

Tel: +32 (0) 71 12 10 00

[investorrelations@bonetherapeutics.com](mailto:investorrelations@bonetherapeutics.com)

### For International Media Enquiries:

#### Consilium Strategic Communications

Marieke Vermeersch

Tel: +44 (0) 20 3709 5701

[bonetherapeutics@consilium-comms.com](mailto:bonetherapeutics@consilium-comms.com)

### For French Media and Investor Enquiries:

#### NewCap Investor Relations & Financial Communications

Pierre Laurent, Louis-Victor Delouvrier and Arthur Rouillé

Tel: + 33 (0)1 44 71 94 94

[bone@newcap.eu](mailto:bone@newcap.eu)

---

*Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.*

---